WinstonWınston
Hologic logo

Hologic

0J5Q.L
48
Medical - Equipment & Services · Healthcare
Price
75.62 GBp
+0.07 (+0.10%)
Market Cap
£16.88B
Exchange
London Stock Exchange
Winston Score
48
Winston is serious
Mixed quality — meaningful strengths and weaknesses.
Data as of Aug 12, 2026 · filings through Dec 31, 2025

Share count falling — buybacks

12.4% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 259.7M (2021) → 227.6M (2025)

Hologic is a medical device and diagnostics company focused almost entirely on women's health. Its main products include mammography machines that screen for breast cancer, tests that detect cervical cancer and sexually transmitted infections, and surgical tools used in gynecology procedures. Hospitals, clinics, and doctors' offices across the United States and internationally are its primary customers.

Hologic makes money by selling its imaging equipment and then generating recurring revenue from the consumable test kits and reagents those machines require. The company operates mainly in the U.S. but also has a meaningful international presence, and it generates roughly $4 billion in annual revenue. Its competitive moat comes from its dominant position in breast imaging and molecular diagnostics, where switching costs are high once a hospital installs its systems. The key risk is that Hologic's revenue surged during COVID-19 due to high demand for its diagnostic tests, and sustaining that elevated revenue base as testing volumes normalize remains an ongoing challenge.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+6.2% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+10.5% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$248M/ year

Declining (-9% vs prior year)

6.1% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.9%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$2.0B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Hologic is growing revenue at 6% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
55.7%
Premium pricing power — 55.7% gross margin
Operating Margin
23.0%
Excellent — 23.0% operating margin
ROCE
3.1%
Weak — 3.1% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+2.2%
Nearly flat sales (+2.2% YoY)
EPS YoY
-23.5%
Earnings shrinking (-23.5% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
202%
Turns 202% of profit into real cash
FCF Margin
23.2%
Converts sales into free cash efficiently (23.2%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.48
Conservative — low debt load (0.48)
Interest Cover
7.69x
Adequate interest coverage (7.7x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
0.3x
Attractive valuation — P/E 0.3

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward
-15.4
SLOWING
Earnings expected to fall — forward P/E higher than today

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial